Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Crespo

Showing results (321-330 of 366) with videos related to

Pageof 37
Sort By:
Journal of Hepatology|June 11, 2018
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, et al.
Molecular Metabolism|November 1, 2019
miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver diseasePablo Fernández-Tussy, David Fernández-Ramos, Fernando Lopitz-Otsoa, et al.
Cell Death & Disease|September 22, 2018
MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosisDavid Fernández-Ramos, Pablo Fernández-Tussy, Fernando Lopitz-Otsoa, et al.
JHEP Reports : Innovation in Hepatology|May 17, 2021
Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injuryPaula Iruzubieta, Naroa Goikoetxea-Usandizaga, Lucía Barbier-Torres, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 25, 2021
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjectsJavier Ampuero, Rocío Aller, Rocío Gallego-Durán, et al.
Nature Communications|December 14, 2017
The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injuryLucía Barbier-Torres, Paula Iruzubieta, David Fernández-Ramos, et al.
Gastroenterologia Y Hepatologia|April 11, 2018
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guidelineRocío Aller, Conrado Fernández-Rodríguez, Oreste Lo Iacono, et al.
Journal of Gastroenterology|April 15, 2024
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosisJavier Ampuero, Rocío Aller, Rocío Gallego-Durán, et al.
JHEP Reports : Innovation in Hepatology|October 16, 2025
Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitisÁlvaro Díaz-González, Ida Schregel, Lorena Carballo, et al.
Gastroenterology|January 31, 2017
Metabolomic Identification of Subtypes of Nonalcoholic SteatohepatitisCristina Alonso, David Fernández-Ramos, Marta Varela-Rey, et al.
Pageof 37

Showing results (321-330 of 366) with videos related to

Sort By:
Pageof 37
Journal of Hepatology|June 11, 2018
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, et al.
Molecular Metabolism|November 1, 2019
miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver diseasePablo Fernández-Tussy, David Fernández-Ramos, Fernando Lopitz-Otsoa, et al.
Cell Death & Disease|September 22, 2018
MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosisDavid Fernández-Ramos, Pablo Fernández-Tussy, Fernando Lopitz-Otsoa, et al.
JHEP Reports : Innovation in Hepatology|May 17, 2021
Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injuryPaula Iruzubieta, Naroa Goikoetxea-Usandizaga, Lucía Barbier-Torres, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 25, 2021
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjectsJavier Ampuero, Rocío Aller, Rocío Gallego-Durán, et al.
Nature Communications|December 14, 2017
The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injuryLucía Barbier-Torres, Paula Iruzubieta, David Fernández-Ramos, et al.
Gastroenterologia Y Hepatologia|April 11, 2018
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guidelineRocío Aller, Conrado Fernández-Rodríguez, Oreste Lo Iacono, et al.
Journal of Gastroenterology|April 15, 2024
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosisJavier Ampuero, Rocío Aller, Rocío Gallego-Durán, et al.
JHEP Reports : Innovation in Hepatology|October 16, 2025
Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitisÁlvaro Díaz-González, Ida Schregel, Lorena Carballo, et al.
Gastroenterology|January 31, 2017
Metabolomic Identification of Subtypes of Nonalcoholic SteatohepatitisCristina Alonso, David Fernández-Ramos, Marta Varela-Rey, et al.
Pageof 37